



Title of side event	Strengthening regional health industries and promoting technology transfer to enhance pandemic resilience and improve health outcomes in LDCs
Lead entity (main organizer)	UNTBLDC, UNIDO
Contact person at lead organizer (name, email, phone)	Bernardo Calzadilla-Sarmiento, <u>b.calzadilla-sarmiento@unido.org</u> Moshe Kao, <u>moshe.kao@un.org</u>
Thematic focus and expected outcome of side event	The COVID19 pandemic has highlighted the close interrelationship between health and economic activity. Many LDCs bear a disproportionate burden of disease which is a significant contribution to the poverty trap in which they find themselves. It is compounded by weak healthcare systems that are particularly fragile and vulnerable to crises.
	Accessing medicines, vaccines and other health technologies of appropriate quality is a vital component of these healthcare systems and one which has been shown to be particularly susceptible to external shocks during the current pandemic. The situation relates to COVID19 vaccines and to other priority vaccines, essential medicines, diagnostics, PPE and other healthcare commodities.
	There is thus a need to build productive capacities for health technologies in LDCs and developing regions of the world and to shorten the value chains so that they become more regionalized and robust.
	There is also the opportunity to work with the global community to explore how such capacities can contribute to a new, post-pandemic order that encourages innovation whilst enabling more equitable access to these products for citizens of developing and least developed countries.
	This session will reflect on issues highlighted by the pandemic such as disruption to supply of PPE, ARVs, diagnostics etc. as well as the challenges to achieving equitable distribution of COVID19 vaccines given current highly constrained global supply.









	It will consider the current situation with regard to local production of essential health technologies and products in LDCs and developing regions and identify the challenges that need to be overcome in order to build robust, sustainable, high-quality sources of essential health technologies and products in such jurisdictions. It will also reflect on how technology transfer and voluntary licensing utilizing these capacities could be facilitated to accelerate access to innovative health technologies.
Contribution to LDC5	 Science, technology and innovation are critical enablers for LDCs to achieve transformational impact towards building back better, attaining resilience and eventually graduating from LDC category. In 2021 the TRIPs flexibilities for LDCs will expire and there is an opportunity to identify sustainable mechanisms that can enable access to innovative healthcare products in LDCs. Furthermore, the challenges in accessing COVID19 vaccine for the developing world have highlighted the need to expand the debate beyond the global legal framework on intellectual property and put in place the industrial supply capacity that can produce the healthcare products in question. This session can help to foster a common understanding on the role of health industry development in improving pandemic resilience and improved health outcomes for LDCs. The session will highlight the importance of investing in STI infrastructure for LDCs and facilitating the mobilization of partnerships and resources to support LDCs in building productive capacities. It will also help to identify priority actions that could be taken to realize the vision of increased self-sufficiency of developing regions and LDCs for priority healthcare products and thus key measures for inclusion in the new 10-year Programme of Action.
Structure and Speakers at side event (TBC)	Moderator – Mr. Moshe Kao, Programme Management Officer Opening Remarks – 20 min - UNIDO, DG, LI Yong - UNTBLDC, MD, Mr. Joshua SETIPA Panel discussion – 30 (Invited Experts – 5-8 min)









Moderator – UNTBLDC
1. Mr. Greg PERRY, Assistant Director General - International
Federation of Pharmaceutical Manufacturers Association
 Dr. Janet BYARUHANGA - African Union Development Agency – NEPAD
 Dr. Babatunde OMILOLA, Manager, Public Health, Security and Nutrition Division
 Dr. Tsepo TSEKOA - Principal researcher and research group leader for biomanufacturing technology demonstration
 Dr Charlemagne GNOULA, - Bureau de Suivi du Programme Présidentiel (BSPP)
Interactive discussion – 30 min
 Incl. statements from member states
Closing remarks – 5 min



